Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTSNYSEMKT:IGCNYSEAMERICAN:LCTXNASDAQ:MGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTSALT5 Sigma$8.70-7.2%$7.69$1.29▼$10.95$163.73M2.31230,535 shs434,578 shsIGCIGC Pharma$0.31-5.2%$0.31$0.25▼$0.50$24.50M1.48337,456 shs214,616 shsLCTXLineage Cell Therapeutics$0.96-9.9%$0.63$0.37▼$1.15$244.34M1.521.46 million shs3.02 million shsMGNXMacroGenics$1.27-3.1%$1.52$0.99▼$5.77$82.65M1.65818,226 shs1.07 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTSALT5 Sigma-7.25%-5.02%-2.90%+110.65%+869,999,900.00%IGCIGC Pharma+0.98%+2.66%-6.65%+4.39%+30,899,900.00%LCTXLineage Cell Therapeutics-9.88%+5.38%+41.21%+96.04%+6.78%MGNXMacroGenics-3.05%-7.30%-14.48%+0.79%-68.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTSALT5 Sigma0.1862 of 5 stars0.03.00.00.01.80.00.0IGCIGC Pharma1.8444 of 5 stars3.50.00.00.02.31.70.0LCTXLineage Cell Therapeutics2.4134 of 5 stars3.51.00.00.01.83.30.6MGNXMacroGenics3.9464 of 5 stars3.21.00.04.42.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTSALT5 Sigma 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.881,154.05% UpsideLCTXLineage Cell Therapeutics 3.00Buy$4.20335.55% UpsideMGNXMacroGenics 2.40Hold$5.71349.94% UpsideCurrent Analyst Ratings BreakdownLatest IGC, ALTS, LCTX, and MGNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025LCTXLineage Cell TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.006/23/2025LCTXLineage Cell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/20/2025MGNXMacroGenicsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.005/14/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $3.005/14/2025MGNXMacroGenicsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$6.00 ➝ $5.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTSALT5 Sigma$12.53M12.12N/AN/A$0.49 per share17.76IGCIGC Pharma$1.24M19.92N/AN/A$0.08 per share3.86LCTXLineage Cell Therapeutics$9.50M23.18N/AN/A$0.35 per share2.76MGNXMacroGenics$149.96M0.53N/AN/A$1.85 per share0.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTSALT5 Sigma-$6.24MN/A0.00∞N/A-38.58%-113.79%-8.96%N/AIGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/ALCTXLineage Cell Therapeutics-$18.61M-$0.12N/AN/AN/A-169.57%-22.64%-15.27%8/6/2025 (Estimated)MGNXMacroGenics-$66.97M-$0.89N/AN/AN/A-36.23%-59.84%-23.45%8/5/2025 (Estimated)Latest IGC, ALTS, LCTX, and MGNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGNXMacroGenics-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTSALT5 SigmaN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/ALCTXLineage Cell TherapeuticsN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTSALT5 Sigma1.260.830.83IGCIGC Pharma0.021.150.98LCTXLineage Cell TherapeuticsN/A3.823.82MGNXMacroGenicsN/A3.283.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTSALT5 Sigma6.27%IGCIGC Pharma3.87%LCTXLineage Cell Therapeutics62.47%MGNXMacroGenics96.89%Insider OwnershipCompanyInsider OwnershipALTSALT5 Sigma4.90%IGCIGC Pharma31.48%LCTXLineage Cell Therapeutics26.80%MGNXMacroGenics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTSALT5 Sigma17017.45 million16.60 millionN/AIGCIGC Pharma6179.69 million54.60 millionN/ALCTXLineage Cell Therapeutics60228.36 million167.16 millionNot OptionableMGNXMacroGenics43063.09 million54.89 millionOptionableIGC, ALTS, LCTX, and MGNX HeadlinesRecent News About These CompaniesMacroGenics (NASDAQ:MGNX) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?June 18, 2025 | marketbeat.comMacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year aheadJune 16, 2025 | investing.comMacroGenics lands $70M 'infusion of cash' to advance clinical programsJune 13, 2025 | bizjournals.comMacroGenics: Working On That Road To RecoveryJune 11, 2025 | seekingalpha.comMacroGenics Shares Rise on Royalty-Purchase AgreementJune 10, 2025 | marketwatch.comMacroGenics Target of Unusually Large Options Trading (NASDAQ:MGNX)June 10, 2025 | marketbeat.comMacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase AgreementJune 10, 2025 | globenewswire.comMacroGenics (NASDAQ:MGNX) Upgraded by Wall Street Zen to "Hold" RatingJune 7, 2025 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Given Average Recommendation of "Hold" by AnalystsJune 4, 2025 | marketbeat.comMacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025June 3, 2025 | globenewswire.comMacroGenics (NASDAQ:MGNX) Upgraded to Hold at Wall Street ZenMay 31, 2025 | marketbeat.comMillennium Management LLC Sells 671,179 Shares of MacroGenics, Inc. (NASDAQ:MGNX)May 27, 2025 | marketbeat.comZacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion TechnologiesMay 23, 2025 | nasdaq.com4 Medical Product Stocks to Watch From a Challenging IndustryMay 21, 2025 | zacks.com6MGNX : 4 Analysts Assess Macrogenics: What You Need To KnowMay 20, 2025 | benzinga.comMacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial ResultsMay 16, 2025 | finanznachrichten.deEarnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50May 16, 2025 | finance.yahoo.comMacroGenics (MGNX) Reports Q1 Loss, Lags Revenue EstimatesMay 13, 2025 | zacks.comMacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comA Look at Macrogenics's Upcoming Earnings ReportMay 12, 2025 | benzinga.comMacroGenics Announces Date of First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGC, ALTS, LCTX, and MGNX Company DescriptionsALT5 Sigma NASDAQ:ALTS$8.70 -0.68 (-7.25%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$8.80 +0.10 (+1.09%) As of 06/26/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.IGC Pharma NYSEMKT:IGC$0.31 -0.02 (-5.24%) Closing price 06/26/2025 03:57 PM EasternExtended Trading$0.31 +0.00 (+0.32%) As of 06/26/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Lineage Cell Therapeutics NYSEAMERICAN:LCTX$0.96 -0.11 (-9.88%) Closing price 06/26/2025 04:10 PM EasternExtended Trading$0.96 +0.00 (+0.07%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.MacroGenics NASDAQ:MGNX$1.27 -0.04 (-3.05%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.30 +0.03 (+2.36%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
